What question did this study set out to answer?

To examine the relationships between oral isosorbide dinitrate dose, plasma pharmacokinetics, and clinical pharmacological effects in patients with angina.

June 1, 1981British Journal of Clinical PharmacologyOpen Access

Kinetics of isosorbide dinitrate and relationships to pharmacological effects

View Full Paper

Ask AI

Bookmark

Why the study?

What are the inter-relationships among oral isosorbide dinitrate dose, pharmacokinetics, and pharmacological effects in angina patients?

Population

12 angina patients

Design

Other

Follow-up

1 week

Authors

HFHL FungJohannes Gutenberg University Mainz EMEF McNiff DRDonald A. RuggirelloUniversity of North Carolina at Pembroke

Discussion

Member takes

Implication

May predispose angina patients to hypotension with chronic qid ISDN; leaves open optimal dosing strategies.

Key Points

To examine the relationships between oral isosorbide dinitrate dose, plasma pharmacokinetics, and clinical pharmacological effects in patients with angina.
Evaluated 12 patients with angina receiving single and chronic oral doses of isosorbide dinitrate at 15, 30, 60, and 120 mg.
Administered chronic dosing four times daily over a one-week duration.
Measured plasma drug concentrations, area under the concentration-time curve from 0 to 6 hours (AUC 0–6 h), intrinsic clearance, and blood pressure changes.
Single doses exhibited dose-proportional AUC (0–6 h), whereas chronic four-times-daily dosing resulted in significant plasma accumulation of intact drug and disproportionate increases in AUC.
Adverse hypotensive effects occurred in five patients following the single 60 mg dose.
Patients experiencing hypotension demonstrated statistically higher AUC and lower intrinsic clearance across 15, 30, and 60 mg doses compared to unaffected patients.

Structured PICO

What are the inter-relationships among oral isosorbide dinitrate dose, pharmacokinetics, and pharmacological effects in angina patients?

Population

12 angina patients

Intervention

Oral isosorbide dinitrate (ISDN) single and chronic doses of 15, 30, 60 and 120 mg (chronic dosing four times a day for 1 week)

Outcome

Drug pharmacokinetics (AUC from 0-6 h, plasma concentration) and pharmacological effectssurrogate

Chronic dosing of isosorbide dinitrate leads to disproportionate accumulation, and lower drug clearance may predispose patients to adverse hypotensive effects.

Cite This Study

Fung et al. (1981) studied this question.

synapsesocial.com/papers/6a72a02bf44fa9f079e009cc https://doi.org/10.1111/j.1365-2125.1981.tb01174.x

View Full Paper

Ask AI

Bookmark

Kinetics of isosorbide dinitrate and relationships to pharmacological effects

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Kinetics of isosorbide dinitrate and relationships to pharmacological effects

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider